Navigation Links
Rare Disease Therapeutics, Inc. Selects Accredo Health Group to Distribute Anascorp® for the Treatment of Centruroides Scorpion Sting Envenomation
Date:9/13/2011

FRANKLIN LAKES, N.J. and MEMPHIS, Tenn., Sept. 13, 2011 /PRNewswire/ -- Rare Disease Therapeutics, Inc. (RDT) announced today that its recently approved Anascorp® (Centruroides (Scorpion) Immune F(ab')2 (Equine) Injection) is now available on the market through Accredo Health Group, Inc. – a wholly owned subsidiary of Medco Health Solutions, Inc. (NYSE: MHS).  On August 3, 2011, Anascorp became the first treatment approved by the United States Food and Drug Administration (FDA) for Centruroides scorpion sting envenomation, and has been awarded orphan drug designation by the FDA, providing a seven-year period of market exclusivity.  Accredo is the sole U.S. specialty distributor of the medication.

(Logo:  http://photos.prnewswire.com/prnh/20100609/MEDCOLOGO)

"Accredo's experience successfully managing the nuances associated with products targeting rare diseases for small patient populations makes pharmaceutical manufacturers, such as Rare Disease Therapeutics, Inc., confident in trusting their product launch to our team," said Accredo President, Frank Sheehy.  "We look forward to working with Rare Disease Therapeutics, Inc. to deliver this important medication to those in need."

Accredo will offer specialty wholesale distribution services of Anascorp to hospitals and other appropriately licensed facilities.

"Rare Disease Therapeutics, Inc. has worked with Accredo for nearly ten years to provide patients with access to our potential life-saving medications for rare diseases," said Rare Disease Therapeutics, Inc. President Milton H. Ellis. "We worked successfully with Accredo to distribute Anascorp during the clinical trial phase, and we are excited to expand our relationship now that Anascorp is available commercially."

To obtain more information call 1-866-830-7437.

About Anascorp®

<
'/>"/>

SOURCE Medco Health Solutions, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. HemaQuest Pharmaceuticals Completes Patient Enrollment in Phase 2 Clinical Study of HQK-1001 in Patients With Sickle Cell Disease
2. Curemark Issued Patent for the Diagnosis of Parkinsons Disease
3. Regulus Therapeutics to Present New Advancements in microRNA Therapeutics for Treatment of Metabolic Diseases and Cancer
4. Anadys Setrobuvir Named One of Windhovers Top 10 Most Interesting Infectious Disease Projects to Watch
5. Galenea and CHDI Foundation Announce Collaboration to Identify Key Synaptic Dysfunction in Huntingtons Disease
6. Californians Recognized For Role In Helping Rare Disease Patients Who Need Lifesaving Therapies
7. Floridians Recognized for Role in Helping Rare Disease Patients Who Need Lifesaving Therapies
8. Californians and Floridians Recognized for Role in Helping Rare Disease Patients Who Need Lifesaving Therapies
9. Better Funding for Research into Blood Diseases Will Save More Lives
10. Alzheimers Drug Discovery Foundation Supports Madera Biosciences with a Grant to Advance Novel Drug Candidates for Alzheimers Disease
11. IRS Proposed Regulations on Orphan Drug Exclusion from Drug Tax Stand to Harm Future Development of Treatments for Rare Disease Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Sept. 19, 2014  The board of directors of ... quarterly cash dividend of $0.42 per share.  ... to stockholders of record at the close of business ... is a global, research-based biopharmaceutical company formed in 2013 ... use its expertise, dedicated people and unique approach to ...
(Date:9/19/2014)... RESEARCH TRIANGLE PARK, N.C. , Sept. 19, ... company focused on cloud-based drug design and development, ... strategy. The company,s mission is to design new ... Phase 1 and 2 partners to further their ... enhance its portfolio investments. To support this business ...
(Date:9/19/2014)... DUBLIN , Sept. 19, 2014 Research ... "Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) ... For the purposes of this report, the human ... The human microbiome market is expected to be ... grow at a CAGR of 22.3% within the forecast period ...
Breaking Medicine Technology:Cloud Pharmaceuticals Announces Partnering Sessions and Presentation Schedule 2Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 2Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 3
... BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) will ... community on Thursday, December 8, 2011 from 8:00 a.m. ... New York City.  Members of BioMarin,s management team and ... product portfolio and advancements in the research and development ...
... 17, 2011 Eli Lilly and Company (NYSE: ... more than $4 million in additional funding to the ... to continue its early phase drug discovery efforts focused ... against tuberculosis, including multidrug-resistant strains known as MDR-TB. In ...
Cached Medicine Technology:BioMarin to Host a Research and Development Day on December 8th 2Lilly Provides Additional Funding to Infectious Disease Research Institute to Identify New Tuberculosis Therapies 2Lilly Provides Additional Funding to Infectious Disease Research Institute to Identify New Tuberculosis Therapies 3Lilly Provides Additional Funding to Infectious Disease Research Institute to Identify New Tuberculosis Therapies 4
(Date:9/21/2014)... 21, 2014 The Laboratory Testing Services ... manufacturers perform tests on items ranging from consumer and ... society, pressure on operators to ensure the safety and ... greater number of government safety regulations and consumer lawsuits ... to sale. Although revenue briefly dipped in 2009 as ...
(Date:9/21/2014)... "I wanted to be able to ... sugary, foul-tasting energy drinks," said an inventor from Fresh ... to drink plain, old coffee. That is why I ... developed ENERG CHEWING GUM to provide a healthy energy ... formula contains nutritious vitamins, minerals and antioxidants. It also ...
(Date:9/21/2014)... 21, 2014 The Illinois Joining ... host a statewide symposium ( tinyurl.com/ILBHC14 ) focused ... their Families. Sponsored by the VNA Foundation, Thresholds, ... Grant, and Health & Disability Advocates, the symposium ... Hilton Hotel in Springfield, IL. The symposium ...
(Date:9/21/2014)... (PRWEB) September 21, 2014 The ... implements and supports electronic medical records (EMR) and ... from federal healthcare legislation during the past five ... so during the five years to 2019. The ... Health Act established Medicare and Medicaid incentives to ...
(Date:9/21/2014)... Discount-Dress.com, a company that specializes ... its decision to implement a new shopping cart software ... across the world. Furthermore, the company has unveiled a ... , The new items come in fashionable designs; all ... to 56 percent off. "We are happy to release ...
Breaking Medicine News(10 mins):Health News:Laboratory Testing Services in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Laboratory Testing Services in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Enhancing Clinical Competence to Serve Veterans, a Statewide Symposium 2Health News:Enhancing Clinical Competence to Serve Veterans, a Statewide Symposium 3Health News:Electronic Medical Records Systems in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Electronic Medical Records Systems in the US Industry Market Research Report Now Available from IBISWorld 3Health News:Electronic Medical Records Systems in the US Industry Market Research Report Now Available from IBISWorld 4Health News:Discount-Dress.com Implements A New Shopping Cart Software And Provides New Beach Wedding Dresses 2
... million, Five-year Grant, from New York State Department of,Health, ... Lead,Poisoned, NEW YORK, Feb. 11 The Lead ... Montefiore,(CHAM) has been named one of three State Regional ... healthcare delivery for children and,pregnant women with elevated blood ...
... Part of MedCath,s Growth Plans, CHARLOTTE, N.C., Feb. ... physician partners today announced plans to double,the number of ... a 120-bed acute care and heart hospital., The ... into 60 inpatient beds, which will be used to ...
... from the UC Davis M.I.N.D. Institute shows that an ... be linked with the repetitive behavior also called ... studies are needed to confirm the outcome, this result ... prenatal period could be a causal factor for the ...
... SOUTH SAN FRANCISCO, Calif., Feb. 11 ... SpA have announced an agreement granting,an exclusive ... distribution of,Anesiva,s Zingo(TM) (lidocaine hydrochloride monohydrate) powder,intradermal ... France,Germany, Netherlands, Belgium and Luxembourg. Under the ...
... Unlike other epilepsy meds, Trileptal was no better than ... -- The epilepsy drug oxcarbazepine (Trileptal) does not seem ... finds. , Migraines affect more than 28 million Americans, ... effective in preventing these severe headaches. For this reason, ...
... American Academy of ... Dermatology, ... that validates the benefits of alpha-hydroxy acid (AHA),at- home peels in ... as lasers and microdermabrasion. The,data were highlighted in the Poster Session ...
Cached Medicine News:Health News:Montefiore Lead Poisoning Prevention ProgramNamed One of Three State Regional Resource Centers 2Health News:MedCath Plans 60-bed Expansion at TexSAn Heart Hospital 2Health News:MedCath Plans 60-bed Expansion at TexSAn Heart Hospital 3Health News:Prenatal exposure to maternal antibodies linked to autistic behaviors in offspring 2Health News:Prenatal exposure to maternal antibodies linked to autistic behaviors in offspring 3Health News:Anesiva and Sigma-Tau Announce Exclusive Marketing and Distribution Agreement for Zingo(TM) in Six European Countries 2Health News:Anesiva and Sigma-Tau Announce Exclusive Marketing and Distribution Agreement for Zingo(TM) in Six European Countries 3Health News:Epilepsy Drug Doesn't Prevent Migraines 2Health News:NeoStrata Research Validates Anti-Aging Benefits of At-Home AHA Peels As Complement to In-Office Non-Invasive Cosmetic Procedures 2
... Super High Density, multi-frequency, linear ... "twist on the UST-5536, this ... it sweeps horizontally as well ... axis so that target lesions ...
Super High Density, multi-frequency, end-fire phased array transducer. Point-and-shoot scanning is the benefit of this transducer....
This is a 3D transducer for endovaginal imaging in OB/GYN....
This is a 3D transducer for endovaginal imaging in OB/GYN....
Medicine Products: